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Abstract
Background: Cell lines are commonly used in various kinds of biomedical research in the world. However, it
remains uncertain whether genomic alterations existing in primary tumor tissues are represented in cell lines and
whether cell lines carry cell line-specific genomic alterations. This study was performed to answer these questions.
Methods: Array-based comparative genomic hybridization (CGH) was employed with 4030 bacterial artificial
chromosomes (BACs) that cover the genome at 1.0 megabase resolution to analyze DNA copy number aberrations
(DCNAs) in 35 primary breast tumors and 24 breast cancer cell lines. DCNAs were compared between these two
groups. A tissue microdissection technique was applied to primary tumor tissues to reduce the contamination of
samples by normal tissue components.
Results: The average number of BAC clones with DCNAs was 1832 (45.3% of spotted clones) and 971 (24.9%) for
cell lines and primary tumor tissues, respectively. Gains of 1q and 8q and losses of 8p, 11q, 16q and 17p were
detected in >50% of primary cancer tissues. These aberrations were also frequently detected in cell lines. In
addition to these alterations, the cell lines showed recurrent genomic alterations including gains of 5p14-15, 20q11
and 20q13 and losses of 4p13-p16, 18q12, 18q21, Xq21.1 and Xq26-q28 that were barely detected in tumor tissue
specimens. These are considered to be cell line-specific DCNAs. The frequency of the HER2 amplification was high
in both cell lines and tumor tissues, but it was statistically different between cell lines and primary tumors (P =
0.012); 41.3 ± 29.9% for the cell lines and 15.9 ± 18.6% for the tissue specimens.
Conclusions: Established cell lines carry cell lines-specific DCNAs together with recurrent aberrations detected in
primary tumor tissues. It must therefore be emphasized that cell lines do not always represent the genotypes of
parental tumor tissues.
Background
Cancer cell lines are routinely used for various kinds of
biomedical research under the assumption that cell lines
reflect the genotypic and phenotypic characteristics of
primary tumor tissues. However, such cell lines do not
always faithfully represent genomic alterations and gene
expression observed in tumor tissue specimens [1-4],
and therefore the use of cell lines may lead to erroneous
conclusions in some instances. In order to avoid erro-
neous conclusions in experiments using the cell lines,
first of all, it is important to clarify the extent of simila-
rities and differences in genomic aberrations between
cancer cell lines and primary cancer tissues.
According to the commonly accepted model for can-
cer development, somatic mutations accumulate in a
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cancers, not only a large number of genomic aberrations
are detected but also genomic instability successively
yields genomic alterations in a cancer cell. This theory
explains why the number of genomic aberrations is
greater in advanced cancers than in early cancers [5-8].
The established cell lines also undergo genomic changes
with multiple passages in culture [9-11]. Some of the
genomic alterations detected in the cell lines are consid-
ered as a result of selective pressure to adapt to the cul-
ture conditions, while others may be just incidental
[12,13]. This theory raises an additional question in
regard to whether there are genomic aberrations specific
for cell lines, or in vitro-specific genomic aberrations. In
this context, it is crucial to distinguish genomic aberra-
tions in tumor tissues from the secondary changes with
cultivation. The differentiation between these aberra-
tions is practically difficult, because available data on
difference in the genomic changes between cell lines
and tumor tissue specimens are very limited at present
[13,14]. The comparison of genomic profiles obtained
from cell lines with those from primary tumor tissues is
o n eo ft h eb e s tw a y st od e t e r m i n et h ed i f f e r e n c ei n
genomic aberrations between cell lines and primary
tumor tissues and to identify recurrent celll lines-speci-
fic genomic aberrations.
This study examined the DNA copy number aberra-
tions (DCNAs) of 24 breast cancer cell lines and 35 pri-
mary breast cancer tissues using array-based
comparative genomic hybridization (aCGH). The present
paper showed that the breast cancer cell lines preserved
genomic alterations detected in primary cancer tissue
specimens and that the cell lines concurrently carried
secondary genomic alterations. Some of the secondary
genomic alterations were recurrent and cell line-specific.
Methods
Cell lines
This study used 24 cell lines established from human
breast cancer as follows: AU565, HCC2218, T-47D,
HCC1954, MDAMB361, UACC812, UACC893, BT474,
SKBR3, HCC38, HCC1008, ZR-75-30, HCC1937,
MDAMB468, HCC1428, ZR-75-1, MCF7, MDAMB231,
MDAMB435S (possibly derived from melanoma),
BT483, HCC1806, Hs578T, MDAMB175VII and
MDAMB415. These cell lines were purchased from
American type Culture Collection (Manassas, VA). The
original histology of these cell lines was as follows: 6
adenocarcinomas, 10 invasive ductal carcinomas, and 8
unknown tumors [15].
Tumor specimen
Thirty-five primary breast cancers that were histologi-
cally classified as invasive duct carcinoma were used. All
tumors were considered to be sporadic. The average age
of patients was 57.6 years, ranging from 31 to 75 years
old. In this series, the expression of estrogen and pro-
gesterone receptors was positive for 27 (77.1% of
tumors) and 19 (54.3%) tumors, respectively. The Insti-
tutional Review Board for Human Use Yamaguchi Uni-
versity Graduate School of Medicine approved the study
protocol and informed consent for this study was
obtained from all patients. A tissue microdissection
technique was used to reduce the contamination of sam-
ples by normal tissue components for array CGH ana-
lyses, as previously described [16]. As a result, the
normal cell contamination of samples was usually
reduced to less than 10%.
Genomic DNA
High-molecular-weight DNA was extracted from each
tumor specimen with a DNA extraction kit (SepaGene,
Sankojyunyaku Co., Tokyo, Japan) according to the
manufacturer’s instructions as previously described
[17-21].
Array-based CGH
The BAC DNA array used in this study consists of 4030
human bacterial artificial chromosome (BAC) clones,
including 356 cancer-related genes, which are spaced
approximately 1.0 Mb across the whole genome (Macro-
Gen, Inc., Seoul, Korea). BAC chip information including
data of end-sequenced BAC clones is available on the fol-
lowing websites: http://www.macrogen.co.kr/eng/biochip/
karyo_summary.jsp. The experiments were performed as
previously described [19-22]. Briefly, tumor DNA and gen-
der-matched reference DNA (Promega, Madison, WI)
were labeled with Cy5 and Cy3-dCTP (PerkinElmer Life
Science, Inc.), respectively, with a random primer labeling
kit (BioPrime® DNA Labeling System, Invitrogen™). For
hybridization, labeled DNA was mixed with Cot-1 DNA
(50 mg, Gibco BRL, Gaithersburg, MD) and ethanol preci-
pitated. The precipitated DNA was dissolved in 40 μlo f
hybridization mix. The probe mixture was denatured at
75°C for 5 min and incubated at 37°C for 60 min for
blocking of repetitive sequences. Arrays were prehybri-
dized with salmon sperm DNA to reduce nonspecific
background staining. The probe mixture was applied to
the array. The arrays were placed in a moist chamber at
37°C for 72 hr for hybridization. The array slides were
washed 2 times in 2× standard saline citrate (2 × SSC),
50% formamide, pH 7.0, at 45°C. The array slides were
washed in phosphate buffer with 0.1% NP-40, pH 8.0,
once in 2 × SCC at room temperature.
Imaging and analysis
After hybridization, the slides were scanned on a Gene-
Pix 4000A scanner (Axon Instruments, Union City, CA)
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5.0 software. Fluorescence images were analyzed with
the MAC Viewer™ software program (Macrogen Inc.)
optimized for analysis of the array as previously reported
[20-22]. Fluorescence spots were defined with the auto-
matic grid feature and adjusted manually. Then the ratio
of the red/green channel of each clone was calculated
and converted to a log2 ratio. The clones with log2
ratios that exceed least than ± 0.25 were considered
gain and loss of the copy number. We defined the log2
ratio >1.0 as amplifications. A part of the cell line CGH
data has been previously reported [23].
Statistical analysis
The clone-by-clone comparison of the copy number was
made between the cell lines and tumor tissue specimens.
The differences in the prevalence of common gains and
losses between cell lines and tumor tissues were deter-
mined with the chi-square test. Differences in the total
number of changes and frequency were tested by Stu-
dent t-test. In this study, the Bonferroni correction was
made to adjust the p-value. A difference was considered
to be significant when the P-value was less than 1.25 ×
10
-5 (0.05/4030).
Results
CGH profiles were considerably different between the
cell lines and tumor tissue specimens (Figure 1), and the
array data reported in this manuscript are available on
the following websites: http://cibex.nig.ac.jp/cibex2/
ExperimentMiame.do?queryExperimentalDesignAcces-
sion=CBX105. The number of DCNAs was more in the
cell lines than in the tissue specimens as a general
trend. The average number of copy number gains and
losses were 651.7 ± 148.8 (standard deviation) and
1180.7 ± 433.8, respectively in cell lines, while they were
424.2 ± 215.9 and 548.0 ± 324.7 in the tumor tissue spe-
cimens (Figure 2). However, no statistical difference was
found between these two groups. The average number
of clones with DNA amplification was statistically differ-
ent between the cell lines and the tissue specimens (P =
0.012), 41.3 ± 29.9 for the cell lines and 15.9 ± 18.6 for
the tissue specimens (Figure 2).
DCNAs were frequently detected on the all chromo-
somes in the cell lines, but inter-regional differences in
the frequency were apparent. DCNAs detected In >50%
of the cell lines were as follows: clones with copy num-
ber gains and losses were detected at 1q, 5p, 8q and 20q
a n da t1 p ,3 p ,4 p ,6 p ,8 p ,9 p ,1 0 q ,1 1 p ,1 3 q ,1 5 q ,1 7 p ,
18q and X, respectively (Figure 1a). DCNAs detected in
>50% of the tissue specimens were as follows: gains of
1q and 8q, and losses of 8p 11q, 16q and 17p were
detected (Figure 1b). There were DCNAs shared by the
cell lines and tumor tissue specimens and recurrent
DCNAs in the tissue specimens were generally frequent
in the cell lines. The copy number gains of 1q and 8q
were frequent in both the cell lines and tissue specimens
(Table 1). In particular, the gain of 1q44 was detected in
13 (54.3%) of 24 cell lines and in 19 (54.3%) of 35 tissue
specimens. The gain of 8q22.1 was detected in 15
(62.5%) of the cell lines and in 22 (62.9%) of the tissue
specimens. The copy number losses of 11q and 17p
were frequent in both the cell lines and the tissue speci-
mens. Notable copy number losses of 17p11.2 and
11q23.2 were frequent; 17p11.2 loss was detected in 13
(54.2%) of the cell lines and 19 (54.3%) of the tissue spe-
cimens and 11q23.2 loss was detected in 15 (62.5%) of
the cell lines and 22 (62.9%) of the tissue specimens
(Table 1).
The clone-by-clone comparison of the DCNAs
between the cell lines and the tumor tissues provided
detailed information concerning the difference in
DCNAs between two different sample groups. Gains of
5p14-p15, 20q11 and 20q13 and losses of 4p13-p16,
18q12, 18q21, Xq21.1 and Xq26-q28 were detected
almost exclusively in the cell lines (Figure 3). For
instance, the copy number gain of clones located on
20q13.33 and 20q13.13 were detected in as many as
75% of the cell lines, but it was a rare event (around 3%
of tumors) in the primary tumor tissues (P = 5.68 × 10
-9
and P = 1.23 × 10
-8, respectively)(Table 2). The fre-
quency of the Xq27.1 loss was detected in 16 (66.7%) of
the cell lines, but not detected in the tissue specimens
(P = 1.53 × 10
-8) (Table 2).
The frequency of amplification was higher in the cell
l i n e st h a ni nt h et i s s u es pecimens (Table 3). DNA
amplification was frequent at a wide chromosomal
region 17q12-q21 in both the cell lines and tissue speci-
mens, though other BAC clones with frequent DNA
amplification were considerably different between these
two sample groups (Table 3). The amplification of the
chromosomal region 17q12 including ERBB2/HER2 was
detected in 10 (41.7%) of 24 cell lines and 6 (17.1%) of
35 tissue specimens (P = 0.037).
Discussion
Making a comparison of the CGH profiles between the
established cell lines and their parental tumor tissue
specimens is practically impossible, because the source
tissue specimens are no longer obtainable. Therefore,
the comparison of the genomic profiles obtained from
cell lines with those from primary tumor tissues is one
of the best ways to determine the difference in genomic
aberrations between cell lines and primary tumor tissues
and to identify recurrent cell lines-specific genomic
aberrations.
The array-based CGH revealed a large number of
DCNAs including recurrent ones in both breast cancer
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tendency that the average number of DCNAs was
greater in cell lines than in primary breast cancer tissue
specimens, 1832.4 (45.5% of spots) and 972.2 clones
(24.1%) for a cell line and tumor tissue, respectively.
This result is consistent with the data reported by Nay-
lor and colleagues [24]. The comparison of CGH pro-
files between cell lines and tumor tissues revealed gains
of 1q and 8q and losses of 8p, 11q, 16q and 17p as
recurrent DCNAs shared by two groups. Although there
are some variations in the CGH patterns of breast can-
cers between studies, copy number gains of 1q, 8q, 11q,
17q and 20q and losses of 6q, 8p, 9p, 13q, 16q and 17p
were previously reported as recurrent aberrations in
breast cancers [14,15,24-27]. Gains of 1q44, 1q21 and
8q21-q23 and a loss of 17p11-p13 were detected in both
of the cell lines and the tumor tissues at high rates
(>50% of both samples). The present observations sup-
port the hypothesis that the cell lines basically preserve
the genomic alterations that have occurred in primary
tumor tissues [13,24]. These recurrent DCNAs detected
in both cell lines and tumor tissues are though to be
closely relevant to the development and progression of
breast cancer. The clone-by-clone comparison of DNA
copy numbers between cell lines and tumor tissues
allowed detection of recurrent DCNAs exclusively in
breast cancer cell lines as well as recurrent DCNAs
shared by two groups. Gains of 5p14-15, 20q11 and
20q13 and losses of 4p13-p16, 18q12, 18q21, Xq21.1
and Xq26-q28 were detected almost exclusively in the
cell lines. Although the resolution of the BAC array
used in this study is low in comparison to the tiling
arrays, this study revealed a distinct difference in the
patterns of the copy number aberrations between pri-
mary tumor tissues and cell lines. When data of cell
lines are compared between the present CGH platform
and others including tiling arrays, the chromosomal
regions identified as copy number aberrations in this
study are compatible with those provided by tiling
arrays [27,28]. Indeed, gains of 8q and 20q were fre-
quently detected by the 4K array slides as well as by til-
ing arrays. The present data provided by the 4K array
platform are thus considered to be reliable.
It is particularly worth noting that some of recurrent
DCNAs that are frequently detected in cell lines are
hardly detected in primary cancer tissues. These DCNAs
correspond to cell line-specific or in vitro-specific altera-
tions [13,24,29]. Interestingly, these recurrent DCNAs
identified in breast cancer cell lines were also detected
in cell lines of other types, such as gastric cancer [30],
lung cancer [31], colon cancer [32] and pancreatic can-
cer cell lines [33]. Established cell lines possibly carry
the cell line-specific DCNAs regardless of the parental
Figure 1 The frequency of DCNAs detected by array-based
CGH in the breast cancer cell lines (n = 24) (a) and the primary
breast cancer tissues (n = 35) (b). Note the apparent similarity of
the DCNA frequency pattern between two groups, gains of 1q, 8q,
17q and chromosome 20 and losses of 8p, 11q, 16q and 17p are
frequent in both groups. However, the frequency of DCNA at each
chromosomal region is different between these two groups, and
other recurrent DCNAs are detected in the cell lines. Gains of 5p
and 20q and losses of 4p, 18q and Xq are highly frequent in the cell
lines in comparison to the tumor tissues. Green lines denote the
frequency of DNA copy number gain in each BAC clone and red
lines denote the frequency of DNA copy number loss in each BAC
clone. Ordinate; frequency of DCNA for each BAC clone on the
array, abscissa; chromosome number.
Figure 2 The average number of DNA copy number gain, loss
and amplification for cell lines (n = 24) and the tumor tissues
(n = 35). The average number of clones with copy number gain is
and 651.7 ± 148.8 and 424.2 ± 215.9 in the cell lines and tumor
tissues, respectively. The average number of clones with copy
number loss is 1180.7 ± 433.8 and 548.0 ± 324.7 in the cell lines
and tumor tissues, respectively. The average number of
amplification clones is 41.3 ± 29.9 and 15.9 ± 18.6 in the tumor
tissues and the cell lines, respectively. The difference is statistically
significant (P = 0.012). White columns; the average number of DNA
copy number gain. Gray columns; the average number of DNA copy
number loss. Black columns; the average number of amplifications.
Black bars; standard deviations. Ordinate; frequency of DCNA for
each BAC clone, abscissa; samples.
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A: Clones with significant difference in frequency of copy number gain between cell lines and tumor tissue specimens
Chromosomal region Candidate genes Frequency (%) P-value
Cell lines Tissue
20q13.33 ZGPAT, BTBD4, 18/24 1/35 5.68551E-09
20q13.13 COX6CP2 18/24 1/33 1.26370E-08
2q22.3 16/24 0/34 2.20899E-08
20q13.31 TFAP2C, PTMAP6 20/24 6/35 4.89015E-07
7p22.3 FLJ20397, UNC84A, 14/24 1/35 1.52990E-06
20q13.12 MYBL2 14/24 1/35 1.52990E-06
20q13.12 ADA, WISP2 14/24 2/35 7.97121E-06
20q11.21 DNMT3B, MAPRE1 11/24 0/35 8.97575E-06
20q11.21-20q11.22 SNTA1 11/24 0/35 8.97575E-06
8q24.3 HSF1, DGAT1, SCRT1 17/24 5/35 1.02265E-05
20q13.33 TPD52L2, DNAJC5 17/24 5/35 1.02265E-05
3q29 LRCH3, IQCG, 12/24 1/35 1.77298E-05
20p13 DEFB32, TRIB3 12/24 1/35 1.77298E-05
20q13.33 ARFGAP1, CHRNA4 19/24 8/35 2.00152E-05
5p14.1 13/24 2/35 2.68521E-05
11q13.3-11q13.4 PPFIA1, CTTN, SHANK2 13/24 2/35 2.68521E-05
20q11.21 BCL2L1, TPX2, MYLK2 13/24 2/35 2.68521E-05
20q13.33 KCNQ2, EEF1A2, PTK6, 17/24 6/35 3.26970E-05
5p15.31 15/24 4/35 3.72069E-05
5p15.2 MARCH6 15/24 4/35 3.72069E-05
5p15.1 BASP1, FTHL10 15/24 4/35 3.72069E-05
6q22.31 16/24 4/31 3.94622E-05
8q24.21 MYC, PVT1, 22/24 14/35 6.40836E-05
7q11.23 POR, TMPIT, DUSP24 9/24 0/35 8.30527E-05
14q22.2-14q22.3 GALIG, LGALS3 DLG7 9/24 0/35 8.30527E-05
19q13.43 ZNF544, ZNF8, HKR2 9/24 0/35 8.30527E-05
20p11.23 ZNF339, RPL15P1 9/24 0/35 8.30527E-05
3q29 TMEM44, FLJ11301 12/24 2/35 8.56953E-05
10p15.3 GTPBP4, IDI2, IDI1 12/24 2/35 8.56953E-05
20p13 CSNK2A1 12/24 2/35 8.56953E-05
20q13.2 ZNF217 17/24 7/35 9.43882E-05
B: Clones with siginificant difference in frequecy of copy number loss between cell lines and tumor tissue specimens
Chromosomal region Candidate genes Frrequency (%) P-value
Cell lines Tissue
Xp11.3 UTX 21/24 1/35 3.98705E-11
Xq27.1 - 16/24 0/35 1.52947E-08
Xq21.1 - 18/24 2/35 3.33574E-08
4p15.1 - 16/24 1/35 1.05951E-07
4p13 - 14/24 0/34 3.16890E-07
18q12.3 RIT2 16/23 2/34 3.88478E-07
Xq26.2 OR2AF1 15/24 1/35 4.14685E-07
Xq27.3 HCP44 15/24 1/35 4.14685E-07
18q21.1 MAPK4 18/24 4/35 7.03535E-07
Xq28 F8, VBP1, RAB39B, CLIC2 PHF10P1 13/24 0/35 8.17519E-07
18q21.1 KIAA0427 17/24 3/34 9.90978E-07
8p12 WRN 18/24 4/34 1.01721E-06
2q34 SPAG16 13/24 0/34 1.10437E-06
Xq26.2 GPC3 14/24 1/35 1.52990E-06
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4p16.3 FLJ35816 15/24 2/35 2.23384E-06
4p15.1 - 15/24 2/35 2.23384E-06
18q12.2 - 15/24 2/35 2.23384E-06
Xq28 SLC14A2, SLC14A1 15/24 2/35 2.23384E-06
18q21.1 KIAA0427 17/24 3/34 9.90978E-07
8p12 WRN 18/24 4/34 1.01721E-06
2q34 SPAG16 13/24 0/34 1.10437E-06
Xq26.2 GPC3 14/24 1/35 1.52990E-06
4p16.3 FLJ35816 15/24 2/35 2.23384E-06
4p15.1 - 15/24 2/35 2.23384E-06
18q12.2 - 15/24 2/35 2.23384E-06
18q12.3 SLC14A2, SLC14A1 15/24 2/35 2.23384E-06
4p15.1 - 17/24 4/34 4.02576E-06
18q21.32 - 17/24 4/34 4.02576E-06
Xq28 CSAG2, MAGEA2B MAGEA12, CSAG1 14/23 2/35 4.27750E-06
4q13.1 EPHA5 8/16 0/35 5.21729E-06
3p22.1 NKTR, ZNF651, KBTBD5 13/24 1/35 5.34274E-06
4p16.3 HD, 13/24 1/35 5.34274E-06
4p13 - 13/24 1/35 5.34274E-06
4q22.1 - 13/24 1/35 5.34274E-06
5q14.3 - 13/24 1/35 5.34274E-06
18q12.1 - 13/24 1/35 5.34274E-06
Figure 3 P-values and chromosomal regions with significant difference in the frequency of DNA copy number gains (black square in
upper part) and losses (gray diamond in lower part). Clones with cell line-specific copy number gains are densely found at 20q11 and
20q13, whereas clones with cell line-specific losses are detected at 4p13-14, 18q12, 18q21, Xq21 and Xq26-28. This figure shows clones with
highly significant difference (p < 0.00005) in the frequency between the cell lines and the tumor tissues. Ordinate; statistic P-values, abscissa;
chromosome number.
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and tissues from which cancer develops [13,34,35].
Breast epithelial cells transformed in vitro show genomic
alterations similar to those of cell lines [36]. Therefore,
taking these observations into consideration, it is legiti-
mate to consider that in vitro environments endow cells
with genomic aberrations of which cell line-specific
DCNAs are critical for cells to survive and proliferate in
vitro. Indeed, it is known that the pattern of CGH pro-
files change in varying degree with the cell passage
numbers [9].
The difference in the CGH profiles found between the
cell lines and tumor tissues is not attributed to just var-
iations in genomic alterations between parental histolo-
gical types, because DCNAs detected exclusively in cell
lines are not explained by the difference in histologic
types [37-39]. Accordingly, this also strengthens the
view that recurrent DCNAs detected exclusively in cell
lines can be called cell line-specific aberrations.
The average number of amplified clones was more
than double in the cell lines than the tumor tissues
(41.3 vs. 15.9). In particular, the frequency of amplifica-
tion for clones on 17q12-q21, encompassing many genes
including ERBB2/HER2 that is the most frequent ampli-
fied gene in breast cancers [40,41], was higher in the
cell lines than in tissue specimens. The amplification
frequency of the BAC clone harboring ERBB2/HER2
was in 41.7% of the cell lines and 17.1% of the tumor
tissues. The amplification of ERBB2/HER2 is usually
detected in no more than 20% of breast cancer patient
[42]. Therefore, it can be said that additional DNA
amplifications occur not only in the chromosomal
region but also in other regions in the cell lines.
Conclusions
The cell lines carry the cell lines-specific DCNAs
together with in vivo alterations. Cell line-specific
DCNAs were as follows: gains of 5p14-15, 20q11 and
Table 2 Clones with recurrent copy number changes shared by cell lines and tissue specimens
A: Clones with recurrent copy number gains shared by cell lines and tissue specimens
Chromosomal region Genes Frequency P-value
Cell lines Tissue
1q44 FLJ10157 13/24 19/35 0.992806112
8q22.1 TSPYL5 15/24 22/35 0.977767962
8q21.3 NBS1, DECR1 14/24 20/35 0.927569885
8q23.1 MGC35555 14/24 20/35 0.927569885
1q21.1 - 12/24 18/35 0.914136773
1q21.2-1q21.3 PIP5K1A, PSMD4, KIAA1441 12/24 18/35 0.914136773
1q23.1 SH2D2A, INSRR, NTRK1 12/24 18/35 0.914136773
1q32.1 MDM4 12/24 18/35 0.914136773
1q42.11 CAPN2, TP53BP2 12/24 17/35 0.914136773
1q44 FLJ32001, CGI-49 12/24 17/35 0.914136773
1q44 OR1C1, OR9H1P, OR11L1 12/24 18/35 0.914136773
7p14.1 TRGJP2, TRGC1, TRGJ1 12/24 18/35 0.914136773
7p14.1 TRGJP1, TRGV11, TRGVB 12/24 17/35 0.914136773
8q24.22 - 12/24 17/35 0.914136773
17q25.3 TBCD 12/24 17/35 0.914136773
1q25.1 TNN, KIAA0040 14/24 21/35 0.898133861
8q21.3 NBS1 14/24 18/35 0.898133861
8q22.2 KCNS2, STK3 14/24 18/35 0.898133861
B; Clones with recurrent copy number losses shared by cell lines and tissue specimens
Chromosomal region Genes Frequency (%) P-value
Cell lines Tissue
17p11.2 DRG2, MYO15A, LLGL1, FLII 13/24 19/35 0.992806112
17p12 LOC388338, HS3ST3B1 15/24 22/35 0.977767962
11q23.2 ZBTB16 12/24 18/35 0.914136773
11q25 SPAS1 ’12/24 18/35 0.914136773
17p13.3 NXN ’12/24 17/35 0.914136773
17p13.1 ASGR1, DLG4, ACADVL 14/24 21/35 0.898133861
17p13.1 MYH3, SCO1, MDS006 14/24 19/34 0.852726956
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Page 7 of 1020q13 and losses of 4p13-p16, 18q12, 18q21, Xq21.1
and Xq26-q28. When cell lines are used as an alterna-
tive to primary tumor tissues, it is therefore important
to keep in mind that cell lines do not always represent
genotypes of parental tumor tissue specimens.
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Table 3 Clones with frequent DNA amplification in breast cancer cell lines and primary tumor tissues
Chromosomal region Candidate genes No, of tumors Frequency (%)
17q12 NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, PERLD1 10 41.7
17q12 PERLD1, ERBB2, GRB7, ZNFN1A3 10 41.7
17q21.1 ZNFN1A3, ZPBP2, GSDML, ORMDL3, GSDM1, PSMD3 8 33.3
8q24.13 ZHX2 7 29.2
5p15.33 TPPP, LOC442127, ZDHHC11 6 25.0
8q24.12 SAMD12 6 25.0
8q24.12 MRPL13, MTBP, SNTB1 6 20.5
8q24.22 TG, 6 25.0
20q13.2 BCAS1, CYP24A1 6 25.0
20q13.2 BCAS1 6 25.0
20q13.2 DOK5 6 25.0
20q13.2 DOK5 6 25.0
20q13.32 PCK1, ZBP1, TMEPAI, 6 25.0
17q12 NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, PERLD1 7 20.0
17q12 PERLD1, ERBB2, GRB7, ZNFN1A3 8 17.1
17q21.1 ZNFN1A3, ZPBP2, GSDML, ORMDL3, GSDM1, PSMD3 6 17.7
8p12 - 5 14.3
8q21.11 PI15 5 14.3
8q21.11 ZFHX4 5 14.3
8q24.21 DDEF1 5 14.3
17q23.3 TEX2 5 14.3
8p12 WHSC1L1, LETM2, FGFR1 4 11.4
8p12-8p11.23 LETM2, FGFR1 4 11.4
8p11.23 TACC1, PLEKHA2 4 11.4
8q21.11 - 4 11.4
8q21.12 IL7 4 11.4
8q21.3 RUNX1T1 4 11.4
8q22.1 - 4 11.4
8q22.3 - 4 11.4
8q23.3 - 4 11.4
8q24.11 - 4 11.4
8q24.13 - 4 11.4
17q23.3 CSH1, CSHL1, GH1, CD79B, SCN4A 4 11.4
-: The relevant clone harbors no genes identified.
The number of clones with DNA amplification that is detected in more than 10% of samples is 101 clones in the cell lines, while it is only 20 clones in tumor tissues.
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